急性缺血性脑卒中的超早期溶栓治疗

doi:10.3969/j.issn.1004-583X.2016.02.010

临床荟萃 ›› 2016, Vol. 31 ›› Issue (2): 178-181.doi: 10.3969/j.issn.1004-583X.2016.02.010

急性缺血性脑卒中的超早期溶栓治疗

孙雪^1,2,阳国平²

1. 中南大学药学院,湖南长沙 4100131;
2. 中南大学湘雅三医院临床药理中心,湖南长沙 410013

收稿日期:2016-01-20 出版日期:2016-02-05 发布日期:2016-04-18
通讯作者: 阳国平,Email:ygp9880@126.com
作者简介:孙雪(1989-),女,硕士研究生,主要从事临床药理学及药代动力学研究,2009～2013年就读于中南大学药学院药学专业,2013年至今为中南大学药学院药剂学专业硕士研究生。
基金资助:
国家“重大新药创制”科技重大专项基金资助项目(2012ZX09303014-001)

Research progress of ultra earlier thrombolysis for acute ischemic stroke

Sun Xue^1,2,Yang Guoping²

1.Pharmacy College of Central South University, Changsha 410013, China;
2. Center of Clinical Pharmacology, the Third Xiangya Hospital of Central South University, Changsha 410013, China

Received:2016-01-20 Online:2016-02-05 Published:2016-04-18
Contact: Yang Guoping,Email:ygp9880@126.com

摘要/Abstract

摘要： 脑卒中是一种高发病率、高致残率、高病死率的急性脑血管疾病,发病后的快速有效治疗可降低复发率和病死率。近年来把握治疗时间窗,对急性缺血性脑卒中进行超早期治疗成为研究的热点。目前急性缺血性脑卒中超早期治疗的方案主要为溶栓治疗,包括动脉溶栓、静脉溶栓、动静脉联合溶栓等。本文将就近年来各种超早期溶栓治疗方案的研究进展进行综述,以期发现适合临床推广应用的治疗方法。

关键词: 脑梗死, 血栓溶解疗法, 组织型纤溶酶原激活物

Abstract: Stroke is an acute cerebrovascular disease with high rate of incidence,mutilation andmortality.Fast and effective treatment after the onset of stroke can decrease the recurrence rate and mortality. In recent years, grasping the treatment time window to treat acute ischemic stroke is becoming a hotspot.The main method for acute ischemic stroke is ultra earlier thrombolysis including intra-arterial thrombolysis,intravenous thrombolysis and a combination of both. This article will review the research progress of all kinds of ultra earlier thrombolysis treatment in recent years to find a suitable method for clinical application.

Key words: brain infarction, thrombolytic therapy, tissue plasminogen activator

中图分类号:

R743.33

孙雪,阳国平. 急性缺血性脑卒中的超早期溶栓治疗[J]. 临床荟萃, 2016, 31(2): 178-181.

Sun Xue,Yang Guoping. Research progress of ultra earlier thrombolysis for acute ischemic stroke[J]. Clinical Focus, 2016, 31(2): 178-181.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2016.02.010

https://huicui.hebmu.edu.cn/CN/Y2016/V31/I2/178

参考文献

[1] Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association[J]. Circulation,2015,131(4):e29-322.
[2] No authors listed. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group [J]. N Engl J Med,1995,333(24):1581-1587.
[3] Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke[J]. N Engl J Med, 2008,359(13):1317-1329.
[4] Emberson J, Lees KR,Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke:a meta-analysis of individual patient data from randomised trials[J]. Lancet, 2014, 384(9958):1929-1935.
[5] Wardlaw JM, Murray V, Berge E, et al. Thrombolysis for acute ischaemic stroke[J]. Cochrane Database Syst Rev, 2014,7:CD000213.
[6] Nakagawara J, Minematsu K, Okada Y,et al. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS)[J]. Stroke, 2010, 41(9):1984-1989.
[7] Dharmasaroja PA, Pattaraarchachai J. Low vs standard dose of recombinant tissue plasminogen activator in treating East Asian patients with acute ischemic stroke[J].Neurol India,2011,59(2):180-184.
[8] 高宏章,陈湛愔,何国林,等. 尿激酶静脉溶栓治疗急性脑梗死有效治疗时间窗分析[J]. 中国实用神经疾病杂志,2014,17(23):75-77.
[9] 石义亭,李德洋,赵毅,等. 大剂量尿激酶超早期静脉溶栓治疗脑梗死的临床研究[J]. 中华医学杂志,2000,80(2):101-103.
[10] 陈德鹏. 尿激酶静脉溶栓治疗超早期脑梗死的临床应用探讨[J]. 中国实用医药,2015,10(14):180-181.
[11] Sugg RM, Noser EA, Shaltoni HM, et al. Intra-arterial reteplase compared to urokinase for thrombolytic recanalization in acute ischemic stroke[J]. AJNR Am J Neuroradiol, 2006,27(4):769-773.
[12] 陈华山,陈振云,熊海刚,等. 瑞替普酶静脉溶栓治疗超早期脑梗死的疗效研究[J],现代实用医学, 2015,27(8):1014-1016.
[13] Jauch EC, Saver JL, Adams HP Jr, et al.Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2013,44(3):870-947.
[14] Christou I, Burgin WS, Alexandrov AV,et al. Arterial status after intravenous TPA therapy for ischaemic stroke: a need for further interventions [J]. Int Angiol, 2001,20(3):208-213.
[15] Adams H, Adams R, Del Zoppo G, et al. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association[J]. Stroke, 2005,36(4):916-923.
[16] Abou-Chebl A. Endovascular treatment of acute ischemic stroke may be safely performed withno time window limit inappropriately selected patients[J]. Stroke, 2010,41(9):1996-2000.
[17] Berkhemer OA, Fransen PS, Beumer D, et al.A randomized trial of intraarterial treatment for acute ischemic stroke[J]. N Engl J Med, 2015,372(1):11-20.
[18] Lewandowski CA, Frankel M, Tomsick TA,et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial[J]. Stroke, 1999,30(12):2598-2605.
[19] 曹红元,石倩千,陈东万,等. 动静脉联合溶栓与静脉溶栓治疗急性缺血性脑卒中的对比研究[J]. 解放军医药杂志, 2014,26(3):43-47.
[20] Wolfe T, Suarez JI, Tarr RW, et al. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke[J].J Stroke Cerebrovasc Dis, 2008,17(3):121-128.
[21] 徐浩文,李明华,管生,等. 动脉溶栓与动静脉联合溶栓治疗急性期缺血性脑卒中的比较[J]. 介入放射学杂志, 2011,20(6):424-428.
[22] 张兆辉,梅思静,吕志华. 动静脉联合溶栓治疗急性缺血性脑卒中的Meta分析[J]. 疑难病杂志,2012,11(7):493-496.
[23] Khatri P, Yeatts SD, Mazighi M, et al.Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke:an analysis of data from the Interventional Management of Stroke (IMS Ⅲ) phase 3 trial[J].Lancet Neurol, 2014, 13(6):567-574.
[24] Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke[J]. N Engl J Med, 2013,368(10):893-903.
[25] Kidwell CS, Jahan R, Gornbein J, et al. A trial of imaging selection and endovascular treatment for ischemic stroke[J]. N Engl J Med, 2013,368(10):914-923.
[26] Ciccone A, Valvassori L, Nichelatti M, et al.Endovascular treatment for acute ischemic stroke[J].N Engl J Med, 2013, 368(10):904-913.
[27] Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection[J]. N Engl J Med,2015,372(11):1009-1018.
[28] Saver JL, Goyal M, Bonafe A,,et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke[J]. N Engl J Med, 2015,372(24):2285-2295.
[29] Saqqur M, Tsivgoulis G, Nicoli F, et al. The role of sonolysis and sonothrombolysis in acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials and case-control studies[J]. J Neuroimaging, 2014,24(3):209-220.
[30] Reinhard M, Taschner CA, H rsch N, et al. Endovascular treatment versus sonothrombolysis for acute ischemic stroke[J]. Cerebrovasc Dis, 2015, 40(5/6):205-214.

急性缺血性脑卒中的超早期溶栓治疗

Research progress of ultra earlier thrombolysis for acute ischemic stroke

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张学谦, 李阳, 徐国栋, 吕佩源. 卵圆孔未闭所致急性脑梗死患者人口学特征、临床及影像学等特征分析[J]. 临床荟萃, 2023, 38(6): 500-503.
[2]	王英南, 赵琦, 白海威, 武丹娜, 魏金梅, 李省江, 李锐凌, 张瑞星. 胃癌合并脑梗死的临床特点及危险因素分析[J]. 临床荟萃, 2023, 38(5): 417-422.
[3]	周琪, 朱燕宾, 栗维宁, 李叔寒, 张秀果. 58例术前发生院内急性脑梗死的老年骨折患者流行病学特征[J]. 临床荟萃, 2023, 38(5): 438-443.
[4]	姚美芬, 丁刚玉, 徐建华, 王国江. 重组组织型纤溶酶原激活剂治疗急性轻型缺血性脑卒中的有效性和安全性[J]. 临床荟萃, 2023, 38(3): 227-231.
[5]	梁炳松, 李育英, 张岐平, 陈英道, 李健. 替罗非班治疗进展性穿支动脉梗死临床疗效的相关因素[J]. 临床荟萃, 2023, 38(12): 1091-1094.
[6]	刘德彬, 陈晓璞, 陈文杰, 黄银婷, 何文贞. 阿司匹林、氯吡格雷抵抗相关基因多态性及其与复发性脑梗死的关系[J]. 临床荟萃, 2022, 37(4): 320-324.
[7]	舒明, 喻贵. 血清炎性因子及凝血功能与急性脑梗死患者神经功能预后的相关性[J]. 临床荟萃, 2022, 37(10): 912-915.
[8]	黄旭冰, 林仰, 蔡雯靖. 银杏二萜内酯葡胺对急性脑梗死患者NSE、hs-CRP及生活质量的影响[J]. 临床荟萃, 2021, 36(9): 786-789.
[9]	鲁奎, 郑龙. 急性脑梗死DWI阴性原因分析[J]. 临床荟萃, 2021, 36(8): 753-756.
[10]	陈礼龙, 刘务朝, 司秋艳, 张建平, 程荣, 吴权. 不同剂量硫酸氢氯吡格雷对脑梗死患者血流动力学指标及血清miR-191、miR-18a水平的影响[J]. 临床荟萃, 2021, 36(7): 608-611.
[11]	巩涛, 胡月圆, 高云, 郭畅, 沈慧楠, 王东玉. H型高血压与LAA型急性脑梗死早期神经功能缺损严重程度的关系[J]. 临床荟萃, 2021, 36(7): 612-615.
[12]	刘仲秋, 初建峰. 尤瑞克林联合阿替普酶溶栓治疗急性脑梗死的疗效及对神经功能与炎症因子的影响[J]. 临床荟萃, 2021, 36(6): 509-512.
[13]	王俊, 肖科金, 高兆玉, 朱胜华, 周祎, 刘晓瑜, 蔡超群. 重组组织型纤溶酶原激活剂治疗循环缺血性脑卒中的短期疗效及预后[J]. 临床荟萃, 2021, 36(5): 421-424.
[14]	陈广鹏, 苗国印, 杨艳琴. 急性脑梗死患者血清VEGF、PCT、hs-CRP表达与脑水肿严重程度的关系[J]. 临床荟萃, 2021, 36(4): 315-318.
[15]	赵杨, 马良, 钟启刚. 谷红注射液联合丹参多酚酸盐对急性脑梗死患者神经功能和血液流变学的影响[J]. 临床荟萃, 2021, 36(3): 212-215.